Centre ban on FDCs: P&G, Glenmark, Reckitt too get HC relief

Image
Press Trust of India New Delhi
Last Updated : Mar 16 2016 | 7:33 PM IST
Five healthcare majors, including Procter and Gamble, Glenmark and Reckitt Benckiser today got interim relief from the Delhi High Court which stayed till March 21 the ban imposed by the government on sale of some of their fixed dose combination (FDC) medicines.
Justice Rajiv Sahai Endlaw said "same orders" would be passed in respect of the five companies which also included Alembic Pharmaceuticals and Piramal Enterprises Ltd as was passed yesterday and day before in the case of pharma majors Pfizer, Abbott Healthcare and Macleods Pharmaceuticals.
As a result of the court's order, the ban on sale of P&G's Vicks Action 500 extra, Reckitt's D'Cold and Piramal's Saridon have been lifted till March 21.
A similar relief has been extended to various cough syrups as well as cold medication sold by Glenmark and Alembic.
Alembic has got the relief with respect to its Zeet and Glycodin cough syrups and Wikoryl cold tablet.
For Glenmark, the drugs which would benefit from the order are its Ascoril and Alex cough syrups, Candid ear drops, Candidbiotic, Candid total antifungal cream and Trigulin anti diabetic medicine.
The court asked the counsel for the companies to give the number of years their products have been in the market and listed the matter for further hearing on March 21 when the pleas of Pfizer, Abbott and Macleods would also be taken up.
The Health Ministry, through a gazette notification, has banned over 300 fixed dose combination drugs, including cough syrups compositions, saying they involve "risk" to humans and safer alternatives were available.
The companies have sought quashing of the notification on the ground that no show cause notice or hearing was granted to them prior to issuing of the notification.
They have alleged that the notification is silent on the aspect as to which expert committee was appointed by Health Ministry to examine the safety and deficiency of the FDCs.
As per the notification,"On the basis of recommendations of an expert committee, the Central government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of said drugs in the country.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 16 2016 | 7:33 PM IST

Next Story